Fueling TPD Drug Discovery: In Vitro Evaluation and Synthesis Strategies

Target Protein Degradation (TPD) has merged as an innovative “event-driven” therapeutic approach, overcoming the limitations of traditional small molecule drugs by enabling the targeting of “undruggable” proteins with high potency and selectivity. It offers a significant advantage by targeting these proteins at low doses, thus bringing new hope for clinical treatment. Molecular glues and PROTACs have emerged as rapidly evolving molecules in the TPD field, however, their complex mechanisms introduce significant hurdles in pre-clinical drug discovery.

The synthesis of TPD molecules, particularly PROTACs, is highly complex due to their large molecule weight and intricate structures. This demands advanced synthetic strategies and the availability of a comprehensive E3 ligand library to achieve precise molecular assembly. Moreover, the in vitro evaluation of degraders relies on robust high-throughput screening methods and the capability to comprehensively profile compounds to ensure accurate assessment of their pharmacological effects. Our approach leverages these capabilities to drive TPD drug discovery.